770 related articles for article (PubMed ID: 26076215)
21. Use of Anti-VEGF Drugs in Retinal Vein Occlusions.
Vilela MA
Curr Drug Targets; 2020; 21(12):1181-1193. PubMed ID: 32342813
[TBL] [Abstract][Full Text] [Related]
22. Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.
Cohen MN; Houston SK; Juhn A; Ho AC; Regillo CD; Vander J; Chiang A
Can J Ophthalmol; 2016 Oct; 51(5):342-347. PubMed ID: 27769324
[TBL] [Abstract][Full Text] [Related]
23. Retinal Vein Occlusion.
Sawada O; Ohji M
Dev Ophthalmol; 2016; 55():147-53. PubMed ID: 26501219
[TBL] [Abstract][Full Text] [Related]
24. Wet age related macular degeneration management and follow-up.
Alexandru MR; Alexandra NM
Rom J Ophthalmol; 2016; 60(1):9-13. PubMed ID: 27220225
[TBL] [Abstract][Full Text] [Related]
25. VEGF: A KEY PLAYER NOT ONLY IN MACULAR DEGENERATION. A REVIEW.
Slíva J
Cesk Slov Oftalmol; 2020; 76(4):1-3. PubMed ID: 33086850
[TBL] [Abstract][Full Text] [Related]
26. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.
Ou WC; Brown DM; Payne JF; Wykoff CC
Am J Ophthalmol; 2017 Aug; 180():8-17. PubMed ID: 28549848
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life.
Schmid MK; Reich O; Faes L; Boehni SC; Bittner M; Howell JP; Thiel MA; Signorell A; Bachmann LM
PLoS One; 2015; 10(8):e0135050. PubMed ID: 26241852
[TBL] [Abstract][Full Text] [Related]
28. Aflibercept in the Treatment of Diabetic Macular Edema: A Review and Consensus Paper.
Avitabile T; Azzolini C; Bandello F; Boscia F; De Falco S; Fornasari D; Lanzetta P; Mastropasqua L; Midena E; Ricci F; Staurenghi G; Varano M
Eur J Ophthalmol; 2017 Nov; 27(6):627-639. PubMed ID: 29077188
[TBL] [Abstract][Full Text] [Related]
29. Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network.
Jampol LM; Glassman AR; Bressler NM
JAMA Ophthalmol; 2015 Sep; 133(9):983-4. PubMed ID: 26087135
[No Abstract] [Full Text] [Related]
30. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
Cai S; Bressler NM
Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425
[TBL] [Abstract][Full Text] [Related]
31. Update on the Use of Anti-VEGF Intravitreal Therapies for Retinal Vein Occlusions.
Jiang Y; Mieler WF
Asia Pac J Ophthalmol (Phila); 2017; 6(6):546-553. PubMed ID: 29204993
[TBL] [Abstract][Full Text] [Related]
32. DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema.
Wykoff CC; Hariprasad SM
Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4):308-12. PubMed ID: 27065368
[No Abstract] [Full Text] [Related]
33. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
Krick TW; Bressler NM
Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
[TBL] [Abstract][Full Text] [Related]
34. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
[TBL] [Abstract][Full Text] [Related]
35. [What can anti-VEGF therapy achieve in clinical routine? : Effectiveness of anti-VEGF therapy in patients with macular diseases in clinical routine on 1492 eyes in Austria].
Wiesinger K; Reinelt P; Ennemoser A; Edelmayr M; Schönherr U
Ophthalmologe; 2017 Jul; 114(7):639-645. PubMed ID: 27815675
[TBL] [Abstract][Full Text] [Related]
36. Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Medication Use.
Thulliez M; Angoulvant D; Pisella PJ; Bejan-Angoulvant T
JAMA Ophthalmol; 2018 May; 136(5):557-566. PubMed ID: 29566105
[TBL] [Abstract][Full Text] [Related]
37. Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections.
Osaka R; Muraoka Y; Miwa Y; Manabe K; Kobayashi M; Takasago Y; Ooto S; Murakami T; Suzuma K; Iida Y; Tsujikawa A
Ophthalmologica; 2018; 239(1):27-35. PubMed ID: 28946138
[TBL] [Abstract][Full Text] [Related]
38. Retinal function determined by flicker ERGs before and soon after intravitreal injection of anti-VEGF agents.
Terauchi G; Shinoda K; Sakai H; Kawashima M; Matsumoto CS; Mizota A; Miyake Y
BMC Ophthalmol; 2019 Jun; 19(1):129. PubMed ID: 31208350
[TBL] [Abstract][Full Text] [Related]
39. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
Pichi F; Elbarky AM; Elhamaky TR
Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
[TBL] [Abstract][Full Text] [Related]
40. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
Chong V
Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
